Učitavanje...
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramu...
Spremljeno u:
| Izdano u: | Onco Targets Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4610887/ https://ncbi.nlm.nih.gov/pubmed/26508880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S79145 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|